Show simple item record

dc.contributor.authorSirima, Sodiomon B
dc.contributor.authorOuedraogo, Alphonse
dc.contributor.authorBarry, Nouhoun
dc.contributor.authorSiribie, Mohamadou
dc.contributor.authorTiono, Alfred B
dc.contributor.authorNébié, Issa
dc.contributor.authorKonaté, Amadou T
dc.contributor.authorBerges, Gloria Damoaliga
dc.contributor.authorDiarra, Amidou
dc.contributor.authorOuedraogo, Moussa
dc.contributor.authorSoulama, Issiaka
dc.contributor.authorHema, Alimatou
dc.contributor.authorDatta, Shrimati
dc.contributor.authorLiang, Yuanyuan
dc.contributor.authorRotrosen, Elizabeth T
dc.contributor.authorTracy, J Kathleen
dc.contributor.authorJamka, Leslie P
dc.contributor.authorNeuzil, Kathleen M
dc.contributor.authorLaurens, Matthew B
dc.date.accessioned2021-01-06T14:43:02Z
dc.date.available2021-01-06T14:43:02Z
dc.date.issued2021-01-08
dc.identifier.urihttp://hdl.handle.net/10713/14289
dc.description.abstractObjectives: The World Health Organization pre-qualified single-dose typhoid conjugate vaccine (TCV) and requested data on co-administration with routine vaccines. The co-administration of Typbar TCV (Bharat Biotech International) with routine group A meningococcal conjugate vaccine (MCV-A) and measles–rubella (MR) vaccine was tested. Methods: This was a double-blind, randomized controlled trial performed in Ouagadougou, Burkina Faso. Children were recruited at the 15-month vaccination visit and were assigned randomly (1:1:1) to three groups. Group 1 children received TCV plus control vaccine (inactivated polio vaccine) and MCV-A 28 days later; group 2 children received TCV and MCV-A; group 3 children received MCV-A and control vaccine. Routine MR vaccine was administered to all participants. Safety was assessed at 0, 3, and 7 days after immunization, and unsolicited adverse events and serious adverse events were assessed for 28 days and 6 months after immunization, respectively. Results: A total of 150 children were recruited and vaccinated. Solicited symptoms were infrequent and similar for TCV and control recipients, as were adverse events (group 1, 61.2%; group 2, 64.0%; group 3, 68.6%) and serious adverse events (group 1, 2.0%; group 2, 8.0%; group 3, 5.9%). TCV generated robust immunity without interference with MCV-A vaccine. Conclusions: TCV can be safely co-administered at 15 months with MCV-A without interference. This novel study on the co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa.en_US
dc.description.urihttps://doi.org/10.1016/j.ijid.2020.10.103en_US
dc.language.isoenen_US
dc.relation.ispartofInternational journal of infectious diseases
dc.subjectBurkina Fasoen_US
dc.subjectCo-administrationen_US
dc.subjectMeasles–rubella vaccineen_US
dc.subjectMeningococcal vaccinesen_US
dc.subjectSub-Saharan Africaen_US
dc.subjectTyphoid conjugate vaccineen_US
dc.titleSafety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ijid.2020.10.103
dc.identifier.pmid33176205
dc.source.journaltitleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
dc.source.volume102
dc.source.beginpage517
dc.source.endpage523
dc.source.countryCanada


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record